NCT06342596

A Study of Carbon-14-Labelled [14C] LY3473329 in Healthy Male Participants

A Phase 1, Open-Label, Two-Part Study of the Disposition and Absolute Bioavailability of [14C]-LY3473329 in Healthy Male Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: Male
• Age: 35 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to evaluate how much of the study drug (LY3473329), administered as a single dose that has the radioactive substance 14C incorporated into it, passes from blood into urine, feces and expired air in healthy male participants. The study will also measure how much of the study drug gets into the bloodstream when taken orally, compared to when injected directly into the vein, how its broken down, and how long it takes the body to get rid of it. The study is conducted in two parts. The study will last up to approximately 9 and 7 weeks for part 1 and 2, respectively.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	[14C]-LY3473329	Administered orally
DRUG	[14C]-LY3473329	Administered IV
DRUG	LY3473329	Administered orally

Timeline

• Start date: 2024-03-05
• Primary completion: 2024-05-01
• Completion: 2024-05-01
• First posted: 2024-04-02
• Last updated: 2024-05-30

Locations

1 site across 1 country: United Kingdom

Regulatory

• FDA-regulated drug study